Izzo Carmine, Visco Valeria, Gambardella Jessica, Ferruzzi Germano Junior, Rispoli Antonella, Rusciano Maria Rosaria, Toni Anna Laura, Virtuoso Nicola, Carrizzo Albino, Di Pietro Paola, Iaccarino Guido, Vecchione Carmine, Ciccarelli Michele
Department of Medicine, Surgery and Dentistry, University of Salerno, Baronissi, Italy (C.I., V.V., G.J.F., A.R., M.R.R., A.L.T., A.C., P.D.P., C.V., M.C.); Department of Advanced Biomedical Sciences, "Federico II" University, Naples, Italy (J.G., G.I.); Department of Medicine, Einstein-Sinai Diabetes Research Center, The Fleischer Institute for Diabetes and Metabolism, Einstein Institute for Aging Research, Albert Einstein College of Medicine, New York, New York (J.G.); Cardiology Unit, University Hospital "San Giovanni di Dio e Ruggi d'Aragona," Salerno, Italy (N.V.); and Vascular Physiopathology Unit, IRCCS Neuromed, Pozzilli, Italy (A.C., C.V.).
Department of Medicine, Surgery and Dentistry, University of Salerno, Baronissi, Italy (C.I., V.V., G.J.F., A.R., M.R.R., A.L.T., A.C., P.D.P., C.V., M.C.); Department of Advanced Biomedical Sciences, "Federico II" University, Naples, Italy (J.G., G.I.); Department of Medicine, Einstein-Sinai Diabetes Research Center, The Fleischer Institute for Diabetes and Metabolism, Einstein Institute for Aging Research, Albert Einstein College of Medicine, New York, New York (J.G.); Cardiology Unit, University Hospital "San Giovanni di Dio e Ruggi d'Aragona," Salerno, Italy (N.V.); and Vascular Physiopathology Unit, IRCCS Neuromed, Pozzilli, Italy (A.C., C.V.)
J Pharmacol Exp Ther. 2023 Jan;384(1):102-108. doi: 10.1124/jpet.122.001210. Epub 2022 Jul 2.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic continues to be a global challenge due to resulting morbidity and mortality. Cardiovascular (CV) involvement is a crucial complication in coronavirus disease 2019 (COVID-19), and no strategies are available to prevent or specifically address CV events in COVID-19 patients. The identification of molecular partners contributing to CV manifestations in COVID-19 patients is crucial for providing early biomarkers, prognostic predictors, and new therapeutic targets. The current report will focus on the role of microRNAs (miRNAs) in CV complications associated with COVID-19. Indeed, miRNAs have been proposed as valuable biomarkers and predictors of both cardiac and vascular damage occurring in SARS-CoV-2 infection. SIGNIFICANCE STATEMENT: It is essential to identify the molecular mediators of coronavirus disease 2019 (COVID-19) cardiovascular (CV) complications. This report focused on the role of microRNAs in CV complications associated with COVID-19, discussing their potential use as biomarkers, prognostic predictors, and therapeutic targets.
由于严重急性呼吸综合征冠状病毒2（SARS-CoV-2）大流行导致发病和死亡，它仍然是一项全球性挑战。心血管（CV）受累是2019冠状病毒病（COVID-19）的关键并发症，目前尚无预防或专门应对COVID-19患者心血管事件的策略。确定导致COVID-19患者心血管表现的分子伴侣对于提供早期生物标志物、预后预测指标和新的治疗靶点至关重要。本报告将重点关注微小RNA（miRNA）在与COVID-19相关的心血管并发症中的作用。事实上，miRNA已被认为是SARS-CoV-2感染中发生心脏和血管损伤的有价值的生物标志物和预测指标。重要声明：确定2019冠状病毒病（COVID-19）心血管（CV）并发症的分子介质至关重要。本报告重点关注微小RNA在与COVID-19相关的心血管并发症中的作用，讨论了它们作为生物标志物、预后预测指标和治疗靶点的潜在用途。
